Ballicules.com

Lemborexant

DAYVIGO

Pronunciation: lem-boe-REX-ant (day-VI-goe)

Lemborexant ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Lemborexant ballicule
Lemborexant DAYVIGO mascot mnemonic cartoon
Visual mnemonic: Lemborexant mascot
“Davy goes Limbo, wrecks it”
Blocks orexin, allowing sleep

What it isDual orexin receptor antagonist; insomnia.

Why this oneIt outperformed extended-release zolpidem on late-night sleep maintenance in older adults.

What limits itNext-morning somnolence, and seven hours must remain before waking. CYP3A4-dependent; Schedule IV.

Lemborexant molecular structure (skeletal formula)
Molecular structure: Lemborexant

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
InsomniaAdults5 mg QHS5-10 mg QHS10 mg QHS

Renal Undefined

Hepatic Moderate impairment: max 5 mg QHS; severe impairment: not recommended

No more than once per night

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No human data; animal toxicity only at high multiples of exposure; registry available

Lactation Transferred into breast milk (low, <2% of maternal dose); monitor infant for excessive sedation

Cost

Lemborexant (DAYVIGO)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/mobrand $/moCostPlus
5 mgtab30 qd—$347.33not offered
10 mgtab30 qd—$347.01not offered

Generic entry2035 est.

NO BOXED WARNINGS

Principal riskNext-morning somnolence; allow seven hours

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability3 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityNext-day somnolence, abnormal sleep behaviors and additive CNS depression.

Open Lemborexant in the interactive console ↗

Memory aids: interaction avatars

Lemborexant CYP3A4 substrate avatar mnemonic
CYP3A4 substrate

Open Lemborexant in the interactive console ↗